1. Home
  2. VCIG vs GANX Comparison

VCIG vs GANX Comparison

Compare VCIG & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VCIG
  • GANX
  • Stock Information
  • Founded
  • VCIG 2013
  • GANX 2017
  • Country
  • VCIG Malaysia
  • GANX United States
  • Employees
  • VCIG N/A
  • GANX N/A
  • Industry
  • VCIG Diversified Commercial Services
  • GANX Biotechnology: Pharmaceutical Preparations
  • Sector
  • VCIG Consumer Discretionary
  • GANX Health Care
  • Exchange
  • VCIG Nasdaq
  • GANX Nasdaq
  • Market Cap
  • VCIG 30.2M
  • GANX 31.5M
  • IPO Year
  • VCIG 2023
  • GANX 2021
  • Fundamental
  • Price
  • VCIG $0.44
  • GANX $1.12
  • Analyst Decision
  • VCIG
  • GANX Strong Buy
  • Analyst Count
  • VCIG 0
  • GANX 4
  • Target Price
  • VCIG N/A
  • GANX $8.25
  • AVG Volume (30 Days)
  • VCIG 305.3K
  • GANX 310.2K
  • Earning Date
  • VCIG 08-06-2024
  • GANX 08-08-2024
  • Dividend Yield
  • VCIG N/A
  • GANX N/A
  • EPS Growth
  • VCIG 61.67
  • GANX N/A
  • EPS
  • VCIG 0.21
  • GANX N/A
  • Revenue
  • VCIG $19,781,731.00
  • GANX N/A
  • Revenue This Year
  • VCIG N/A
  • GANX $1,009.10
  • Revenue Next Year
  • VCIG N/A
  • GANX N/A
  • P/E Ratio
  • VCIG $2.03
  • GANX N/A
  • Revenue Growth
  • VCIG 91.25
  • GANX N/A
  • 52 Week Low
  • VCIG $0.42
  • GANX $1.07
  • 52 Week High
  • VCIG $9.35
  • GANX $5.33
  • Technical
  • Relative Strength Index (RSI)
  • VCIG 26.18
  • GANX 33.74
  • Support Level
  • VCIG $0.48
  • GANX $1.22
  • Resistance Level
  • VCIG $0.53
  • GANX $1.24
  • Average True Range (ATR)
  • VCIG 0.04
  • GANX 0.08
  • MACD
  • VCIG -0.00
  • GANX 0.04
  • Stochastic Oscillator
  • VCIG 9.23
  • GANX 20.00

About VCIG VCI Global Limited

VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development solution consultancy. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology Consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment which focuses on listing solutions, investor relations, and boardroom strategies consultancy. It has established a diverse local and international clientele, providing them with its services in both local and cross-border listings. Its role begins with pre-listing diagnosis and planning to the finalization of the entire listing process.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.

Share on Social Networks: